Lv1
30 积分 2022-07-05 加入
[203/212Pb]Pb-VMT-α-NET as a novel theranostic agent for targeted alpha radiotherapy—first clinical experience
16小时前
待确认
225Ac/89Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4–Positive Triple-Negative Breast Cancer
4天前
已完结
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
10天前
已完结
Design, preclinical evaluation, and first-in-human PET study of [68Ga]Ga-PSFA-01: a PSMA/FAP heterobivalent tracer
25天前
已完结
Synthesis of piperazine-based fluorinated fibroblast activation protein inhibitors for the development of a novel 18F-labeled PET imaging probe
25天前
已完结
99mTc-Labeled Quinolone-Based Novel Skeletal Tracers for Tumor Visualization through Fibroblast Activation Protein
25天前
已完结
Clinical comprehensive evaluation of [18F]AlF-FAP-NUR PET: multi-time-point imaging, head-to-head comparison with [18F]FDG
1个月前
已完结
Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial
1个月前
已完结
Noncovalently functionalized carbon microspheres for separating no-carrier added 177Lu from real neutron-irradiated 176Yb target
1个月前
已完结
Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy
1个月前
已完结
皖公网安备34019202002308
